Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares
Definium Therapeutics CEO Robert Barrow recently sold 31,550 shares of the company's common stock, amounting to around $1.15 million. The shares were traded at prices between $36.24 and $36.98, with an average sale price of $36.57 per share. Presently, the company's stock is trading at $38.21, which is close to its InvestingPro Fair Value.
This sale was made to fulfill tax obligations related to the settlement of vested restricted stock units, as part of a pre-arranged sell-to-cover transaction under a Rule 10b5-1 trading plan initiated on June 15, 2022. Following these share sales, Mr. Barrow now directly owns 2,213,090 shares of Definium Therapeutics Inc.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
